## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Confirmation No.:

ALMIRANTE et al.

Group Art Unit:

Application Serial No.: 10/566,292

Examiner:

Filed: January 27, 2006

Attorney Docket No.: 026220.00073

For: ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES

## INFORMATION DISCLOSURE STATEMENT

**Commissioner for Patents** P.O. Box 1450 Alexandria, Virginia 22313-1450

March 30, 2006

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached Form PTO-SB08. Unless otherwise indicated herein, one copy of each item(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

mailing	This Information Disclosure Statement is being filed (a) within three is of the U.S. filing date or the date of filing a CPA, OR (b) before the grate of a first Office Action on the merits in the present application, or (c) upanies a Request for Continued Examination. No certification or fee is ed.	
<ol> <li>This Information Disclosure Statement is being filed more the months after the U.S. filing date AND after the mailing date of the file Action on the merits, but before the mailing date of a Final Rejection or Allowance.</li> </ol>		
	a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).	
	b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).	

	CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
month Notice petitio our ch §1.17( Depos	This Information Disclosure Statement is being filed more than three is after the U.S. filing date and after the mailing date of a Final Rejection or e of Allowance, but before payment of the Issue Fee. Applicant(s) hereby in(s) that the Information Disclosure Statement be considered. Attached is neck in the amount of \$130.00 in payment of the petition fee under 37 CFR (i)(1). Please charge any fee deficiency or credit any overpayment to sit Account No. 01-2300 as needed to ensure consideration of the disclosed nation.
	a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
	b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

Respectfully submitted,

Richard J. Berman Registration No. 39,107

Customer No. 004372 Arent Fox PLLC 1050 Connecticut Avenue, N.W., Suite 400 Washington, D.C. 20036-5339

Tel: (202) 857-6000 Fax: (202) 638-4810

RJB/pdc Enclosures MAR 3 0 2006

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE enwork reduction Act of 1993, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08b (08-03)

Stuction Act of a Under the Paperwork Substitute for form 1449B/PTO Complete if Known **Application Number** 10/566,292 INFORMATION DISCLOSURE Filing Date January 27, 2006 STATEMENT BY APPLICANT ALMIRANTE et al. First Named Inventor Form PTO/SB/08b Art Unit **Examiner Name** 026220-00073 Attorney Docket Number Sheet

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
		BALSAMO et al.; NO-sartans: new class of potential cardiovascular drugs, Abstracts of Papers, 14 <sup>th</sup> Camerino-Noordwijkerhout Symposium "Ongoing progress in the receptor chemistry", Società Chimica Italiana: Camerino, 2003, p. 47, 117	·		
		CALDERONE et al.; NO-sartans: new class of potential cardiovascular drugs, Raccolta degli atti, X Congresso Nazionale della Società' Italiana di ricerche cardiovascolari (S.I.R.C.), Roma; CLUEB: Bologna, 2003, p. 139, 13			
	<del>                                     </del>				

	The same of the sa
Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.